Racial/ethnic disparities: need more work!

Por Landgren, Ola
Publicado no Blood (2017)

Shall we treat smoldering multiple myeloma in the near future?

Por Landgren, Ola
Publicado no Hematology Am Soc Hematol Educ Program (2017)

Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology

Por Landgren, Ola
Publicado no Hematology Am Soc Hematol Educ Program (2010)

HIV, EBV, and monoclonal gammopathy

Por Mailankody, Sham, Landgren, Ola
Publicado em 2013

A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival

Por Kazandjian, Dickran, Landgren, Ola
Publicado no Semin Oncol (2016)

New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma

Por Landgren, Ola, Rajkumar, S. Vincent
Publicado no Clin Cancer Res (2016)

Development of Early Treatment Strategies for High-Risk Myeloma Precursor Disease in the Future

Por Landgren, Ola, Rajkumar, S. Vincent
Publicado no Semin Hematol (2011)

Delaying the Use of High-Dose Melphalan With Stem Cell Rescue in Multiple Myeloma is Ready for Primetime

Por Kazandjian, Dickran, Landgren, Ola
Publicado no Clin Adv Hematol Oncol (2019)

Autoimmunity and Lymphomagenesis

Por Goldin, Lynn R., Landgren, Ola
Publicado em 2009

How I treat smoldering multiple myeloma

Por Ghobrial, Irene M., Landgren, Ola
Publicado no Blood (2014)

Biological frontiers in multiple myeloma: From biomarker identification to clinical practice

Por Landgren, Ola, Morgan, Gareth J.
Publicado no Clin Cancer Res (2013)

Thromboprophylaxis in multiple myeloma: is the evidence there?

Por Kristinsson, Sigurdur Yngvi, Landgren, Ola
Publicado no Expert Rev Anticancer Ther (2012)

Multiple Myeloma Precursor Disease

Por Landgren, Ola, Waxman, Adam Justin
Publicado no JAMA (2010)

What Causes Waldenström’s Macroglobulinemia: Genetic or Immune-Related Factors, or a Combination?

Por Kristinsson, Sigurdur Y., Landgren, Ola
Publicado no Clin Lymphoma Myeloma Leuk (2011)

Polyclonal Immunoglobulin Free Light Chains as a Potential Biomarker of Immune Stimulation and Inflammation

Por Hutchison, Colin A., Landgren, Ola
Publicado no Clin Chem (2011)

Bortezomib to Treat the TEMPI Syndrome

Por Kwok, Mary, Korde, Neha, Landgren, Ola
Publicado no N Engl J Med (2012)

Prevalence, clinical aspects, and natural history of IgM MGUS

Por McMaster, Mary L., Landgren, Ola
Publicado no Cytometry B Clin Cytom (2010)

Myeloma and Second Primary Cancers

Por Landgren, Ola, Thomsas, Anish, Mailankody, Sham
Publicado no N Engl J Med (2011)

Management of multiple myeloma during COVID-19 pandemic

Por Jethava, YS, Fonseca, Rafael, Landgren, Ola
Publicado no Leuk Res Rep (2020)

Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions

Por Landgren, Ola, Kyle, Robert A., Rajkumar, Vincent
Publicado em 2009